Campos E C, Schiavi C, Benedetti P, Bolzani R, Porciatti V
Department of Ophthalmology, University of Modena, Italy.
Graefes Arch Clin Exp Ophthalmol. 1995 May;233(5):307-12. doi: 10.1007/BF00177654.
Citicoline has been used to improve consciousness levels in cerebral trauma and as a complement for levodopa in Parkinson's disease. It has also been shown that severe glaucomatous visual field deficits improve for at least 4 months with the use of citicoline. In this paper, preliminary results are presented of an open and a double-blind study on the effect of citicoline in amblyopia.
The open study was started in 1991. Fifty patients with amblyopia were treated with citicoline (1000 mg i.m. daily for 15 days). They were selected from an age group beyond the plastic period of the visual system. Occlusion or other types of anti-amblyopic treatment were never used at the same time as citicoline. A double-blind study was conducted on 10 more patients, randomly assigned to a treatment or placebo group and followed for 6 months. A statistical test for repeated measures was performed on all the results.
A statistically significant improvement in visual acuity was found both for the amblyopic and the sound eye in 46 of the 50 patients (92%). The behaviour was different for normal and amblyopic eyes. The improvement remained stable for at least 4 months. These results have been substantiated by the double-blind study. No side effects were observed.
Citicoline improves visual acuity, at least temporarily, in amblyopic patients beyond the plastic period of the visual system. Our results suggest that trials of citicoline as a medical treatment of amblyopia are warranted.
胞磷胆碱已被用于提高脑外伤患者的意识水平，并作为帕金森病左旋多巴治疗的补充药物。此外，研究表明，使用胞磷胆碱可使严重青光眼性视野缺损至少在4个月内得到改善。本文介绍了胞磷胆碱治疗弱视的一项开放性研究和一项双盲研究的初步结果。
开放性研究始于1991年。50例弱视患者接受胞磷胆碱治疗（每日1000mg肌肉注射，共15天）。他们选自视觉系统可塑性时期之后的年龄组。在使用胞磷胆碱治疗期间从未同时使用过遮盖或其他类型的弱视治疗方法。另外10例患者进行了双盲研究，随机分为治疗组或安慰剂组，随访6个月。对所有结果进行了重复测量的统计学检验。
50例患者中有46例（92%）弱视眼和健眼的视力均有统计学意义的提高。正常眼和弱视眼的表现有所不同。视力改善至少持续稳定4个月。双盲研究证实了这些结果。未观察到副作用。
胞磷胆碱可提高视觉系统可塑性时期之后的弱视患者的视力，至少是暂时提高。我们的结果表明，有必要对胞磷胆碱作为弱视药物治疗进行试验。
